However, Mb might gain clinical relevance if it could be validated as a novel therapy target of cancer, for example, by applying carbon monoxide in sub-toxic concentrations, as has been suggested by Dr Wittenberg at the O2BIP meeting in Aarhus in 2008, which clearly warrants further study. This evidence concerns the gene MB and cancer.